Northwest Biotherapeutics, Inc. (NWBO)
Stock Price:
$0.353 USD
0.013 (3.68%)
Updated Aug 7, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
252.97M |
| Revenue (ttm) |
2.64M |
| Net Income (ttm) |
3.38M |
| Shares Out |
710.28M |
| EPS (ttm) |
0.01 |
| PE Ratio |
35.25 |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$0.353 |
| Previous Close |
$0.340 |
| Change ($) |
0.013 |
| Change (%) |
3.68% |
| Day's Open |
0.347 |
| Day's Range |
0.334 - 0.368 |
| Day's Volume |
1,469,634 |
| 52-Week Range |
0.140 - 0.419 |
More Stats
| Market Cap |
252.97M |
| Enterprise Value |
269.42M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
710.28M |
| Float |
679.41M |
| EPS (basic) |
n/a |
| EPS (diluted) |
0.01 |
| FCF / Share |
-0.05 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
2.84% |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
14.14M |
| Short Ratio |
13.54 |
| Short % of Float |
15.09% |
| Beta |
1.62 |
| PE Ratio |
35.25 |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
95.79 |
| PB Ratio |
n/a |
| Revenue |
2.64M |
| Operating Income |
-27.43M |
| Net Income |
3.38M |
| Free Cash Flow |
-29.91M |
| Net Cash |
-16.45M |
| Net Cash / Share |
-0.02 |
| Gross Margin |
-423.32% |
| Operating Margin |
-1,038.62% |
| Profit Margin |
127.80% |
| FCF Margin |
-1,132.34% |
| ROA |
-101.89% |
| ROE |
n/a |
| ROIC |
-30.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
15.1
Current: $0.353
High
15.1
Target: 15.10
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 2.41 | 0.41 | 0.34 | 0.62 | 1.74 | 1.45 | 0.81 | 0.77 | 0.01 | 0.01 |
| Revenue Growth | 484.95% | 22.62% | -46.07% | -64.17% | 19.6% | 79.73% | 4.79% | 7620% | 0% | - |
| Gross Profit | 2.41 | 0.41 | 0.34 | 0.62 | 1.74 | 1.45 | 0.81 | 0.77 | 0.01 | 0.01 |
| Operating Income | -27.46 | -41.48 | -54.68 | -79.27 | -126 | -101 | -55.47 | -43.83 | -26.79 | -15.35 |
| Net Income | -20.30 | -35.79 | -73.14 | -80.21 | -115 | -136 | -65.79 | -67.32 | -32.83 | -27.37 |
| Shares Outstanding | 564 | 440 | 243 | 111 | 77.71 | 59.25 | 32.87 | 11.76 | 5.89 | 4.19 |
| Earnings Per Share | -0.04 | -0.12 | -0.31 | -0.77 | -1.48 | -2.29 | -2.00 | -5.72 | -5.58 | -6.56 |
| Operating Cash Flow | -31.86 | -34.59 | -36.50 | -55.65 | -79.71 | -54.58 | -37.80 | -22.75 | -14.71 | -6.38 |
| Capital Expenditures | -0.36 | 45.40 | 0.21 | -4.94 | -6.75 | -33.73 | - | -0.03 | -0.05 | -0.04 |
| Free Cash Flow | -32.22 | 10.82 | -36.28 | -60.59 | -86.46 | -88.30 | -37.80 | -22.79 | -14.76 | -6.42 |
| Cash & Equivalents | 0.37 | 22.22 | 0.12 | 6.87 | 22.70 | 14.26 | 18.50 | 7.35 | 0.02 | 0.15 |
| Total Debt | 18.03 | 16.80 | 31.43 | 31.71 | 22.81 | 23.68 | 1.22 | 3.87 | 15.26 | 9.95 |
| Net Cash / Debt | -17.66 | 5.43 | -31.31 | -24.84 | -0.11 | -9.42 | 17.28 | 3.47 | -15.23 | -9.80 |
| Assets | 9.13 | 24.67 | 48.91 | 52.91 | 70.80 | 56.46 | 18.78 | 7.57 | 0.21 | 0.29 |
| Liabilities | 52.70 | 71.83 | 96.20 | 79.41 | 75.47 | 91.48 | 19.69 | 12.63 | 52.39 | 27.98 |
| Book Value | -43.57 | -47.16 | -67.33 | -26.50 | -4.68 | -35.03 | -9.82 | -16.07 | -52.17 | -27.68 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Northwest Biotherapeutics, Inc. |
| Country |
United States |
| Employees |
17 |
| CEO |
Linda F. Powers |
Stock Information
| Ticker Symbol |
NWBO |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: NWBO |
Description
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L, a product in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, a product in Phase I/II clinical trials to treat various types of inoperable solid tumor cancers. The company was founded in 1996 and is headquartered in Bethesda, Maryland.